Kang Yuan Pharmaceuticals Receives Clinical Trial Approval for Qihuang Zhengqi Granules on July 21

According to Jin10, Kang Yuan Pharmaceuticals announced on July 21 that it has received a Clinical Trial Approval Notice from China's National Medical Products Administration for Qihuang Zhengqi Granules. The herbal granule is designed to replenish qi and nourish blood to treat cancer-related fatigue and qi-blood deficiency syndrome.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments